Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2024.2607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
BMC Med
October 2024
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Lazertinib is a new type of medicine that helps treat a kind of lung cancer called NSCLC, especially for people whose cancer got worse after other treatments.
- In a study with 78 patients, those taking lazertinib lived for an average of about 39 months and had good survival rates at 1, 2, and 3 years.
- The study found that checking for certain cancer genes in the blood can help predict how well patients will respond to lazertinib treatment.
The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer.
JAMA Oncol
October 2024
Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York.
A Real-World Study of Patient Characteristics and Clinical Outcomes in Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.
Cancers (Basel)
March 2024
Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Article Synopsis
- * In a study of 56 patients, those eligible for FLAURA had a longer median time to treatment discontinuation (31.1 months) compared to the ineligible group (12.2 months), indicating better outcomes for eligible patients.
- * Overall survival among all patients was 32.0 months, but it varied greatly between groups, prompting the need for future trials to consider broader patient characteristics for more applicable results in everyday clinical settings.
Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
Ann Oncol
March 2024
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol
January 2024
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- A global phase III trial evaluated the effectiveness of combining amivantamab with chemotherapy (carboplatin-pemetrexed), with and without lazertinib, in treating patients with advanced non-small-cell lung cancer (NSCLC) who have EGFR mutations and have progressed on previous treatment.
- The study involved 657 patients and compared three treatment groups: amivantamab-lazertinib-chemotherapy, amivantamab-chemotherapy, and chemotherapy alone, with a focus on progression-free survival (PFS) as the main outcome.
- Results showed that both amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy resulted in significantly longer PFS and
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!